Every material Form 8-K Voyager Therapeutics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Voyager Therapeutics reported third quarter 2026 results, with collaboration revenue down sharply from a year earlier while its net loss narrowed. The company said its cash runway now extends into the second quarter of 2028, and it expects tau PET imaging data from its VY7523 trial in the fourth quarter of 2026.
Collaboration revenue was $4.0 million for Q3 2026, down from $13.4 million in Q3 2025, mainly due to lower Neurocrine collaboration revenue.
Net loss was $24.7 million, or $0.40 per share, versus $27.9 million, or $0.47 per share, in Q3 2025.
Research and development expenses fell to $24.4 million from $35.9 million; general and administrative expenses fell to $6.1 million from $8.1 million.
Cash, cash equivalents and marketable securities were $132.1 million as of September 30, 2026.
Voyager Therapeutics said its board appointed Chief Business Officer and Chief Operating Officer Robin Swartz as President, effective immediately, and expects her to succeed CEO Alfred Sandrock after initial acute safety data from the VY1706 Alzheimer's trial, anticipated in the first quarter of 2027. Dr. Sandrock is expected to remain on the board, and Ms. Swartz's new employment agreement sets her base salary at $625,000 with severance protections that include acceleration of equity vesting after a sale event.
Robin Swartz appointed President effective October 20, 2026; she is also expected to succeed Alfred Sandrock as CEO after initial VY1706 safety data, anticipated in Q1 2027
Annualized base salary of $625,000 with a target annual cash bonus of 50% of base salary
Grants effective November 1, 2026: option to buy 318,500 shares and restricted stock units covering 68,250 shares
Severance if terminated without cause or for good reason; full equity acceleration if within 12 months after a sale event
Voyager Therapeutics reported second quarter 2026 results. Collaboration revenue fell to $3.2 million from $5.2 million, while the net loss narrowed to $24.5 million from $33.4 million, and cash, cash equivalents and marketable securities were $148.8 million as of June 30, 2026. The company said the cash is expected to fund planned operations into 2028 and that VY7523 tau PET imaging data and VY1706 dosing are both expected in Q4 2026.
Collaboration revenue was $3.2 million, down from $5.2 million a year earlier, mainly due to lower revenue under the Neurocrine collaboration.
Research and development expenses were $22.0 million, down from $31.3 million, which the company attributed to program and platform prioritization.
Net loss was $24.5 million, or $0.40 per share, compared with a net loss of $33.4 million, or $0.57 per share, a year earlier.
Cash and marketable securities were $148.8 million at June 30, 2026, with runway expected into 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Voyager Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →